Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Natalizumab in moderately to severely active Crohn's Disease with elevated CRP
NCT00078611Phase 3Completed
- Sponsor
- Biogen
- Start
- Mar 2004
- Primary completion
- Mar 2005
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of natalizumab in Crohn's disease, sponsored by Biogen. Started Mar 2004; status: completed.
02
Drugs
natalizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT00078611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00078611.